Who Paid My Doc
Adaora Uzodi
Pediatric Infectious Diseases Baton Rouge, LA Medical Doctor
NPI 1316206816 CMS profile 599211
8200 Constantin Blvd Fl 4, Baton Rouge, LA 70809
General payments
$625
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$3,156
Through program year 2025, Adaora Uzodi of Baton Rouge, LA is reported in the CMS Open Payments database as having received $625 across 30 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,156 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 57th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $188 | 7 | |
| 2024 | General | $144 | 7 | |
| 2023 | General | $70 | 4 | |
| 2022 | General | $67 | 4 | |
| 2021 | General | $73 | 4 | |
| 2020 | General | $51 | 3 | |
| 2019 | General | $32 | 1 |
Beside peers
- Adaora Uzodi
- Pediatric Infectious Diseases median
- Middle half of Pediatric Infectious Diseases
- National median
In program year 2025, general payments to Adaora Uzodi were reported at $188. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.
Show as a table
| Year | Adaora Uzodi | Pediatric Infectious Diseases median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $32 | $175 | $34–$2,175 | $163 |
| 2020 | $51 | $521 | $34–$6,009 | $114 |
| 2021 | $73 | $1,077 | $39–$4,557 | $132 |
| 2022 | $67 | $232 | $53–$6,196 | $149 |
| 2023 | $70 | $140 | $52–$4,662 | $160 |
| 2024 | $144 | $198 | $52–$3,860 | $164 |
| 2025 | $188 | $126 | $41–$2,094 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
30 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Infectious Diseases in Louisiana
Joseph Bocchini
Pediatric Infectious Diseases · Shreveport, LA
John Vanchiere
Pediatric Infectious Diseases · Shreveport, LA
Patricia Pichilingue Reto
Pediatric Infectious Diseases · Shreveport, LA
Gayatri Mirani
Pediatric Infectious Diseases · New Orleans, LA
Russell Vandyke
Pediatric Infectious Diseases · New Orleans, LA
Margarita Silio
Pediatric Infectious Diseases · New Orleans, LA
Related records
Pediatric Infectious Diseases in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Infectious Diseases
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.